美国辉宝 2026年季度报告

OR ☐TRANSITION REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period fromtoCommission File Number: 001-36410 Phibro Animal Health Corporation (Exact name of registrant as specified in its charter) ClassA Common Stock, $0.0001par value per share Nasdaq Stock Market Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d)of theSecurities Exchange Act of 1934 during the preceding 12months (or for such shorter period that the registrant was required to filesuch reports), and (2)has been subject to such filing requirements for the past 90days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12months (or for such shorterperiod that the registrant was required to submit such files.) Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, asmaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”“smaller reporting company,” and “emerging growth company” in Rule12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☐Emerging growth company☐ Accelerated filer☒Smaller reporting company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transitionperiod for complying with any new or revised financial accounting standards provided pursuant to Section13(a)of the ExchangeAct.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act). Yes☐No☒ As of January 30, 2026, there were 20,623,682 shares of the registrant’s ClassA common stock, par value $0.0001 pershare, and 19,911,034 shares of the registrant’s ClassB common stock, par value $0.0001 per share, outstanding. PHIBRO ANIMAL HEALTH CORPORATION TABLE OF CONTENTS PARTI—FINANCIAL INFORMATIONItem1.Financial Statements (unaudited)3Consolidated Statements of Operations3Consolidated Statements of Comprehensive Income4Consolidated Balance Sheets5Consolidated Statements of Cash Flows6Consolidated Statements of Changes in Stockholders’ Equity7Notesto Consolidated Financial Statements8Item2.Management’s Discussion and Analysis of Financial Condition and Results of Operations25Item3.Quantitative and Qualitative Disclosures About Market Risk44Item4.Controls and Procedures44PARTII—OTHER INFORMATIONItem1.Legal Proceedings44Item1A. Risk Factors44Item2.Unregistered Sales of Equity Securities and Use of Proceeds44Item3.Defaults Upon Senior Securities44Item4.Mine Safety Disclosures45Item5.Other Information45Item 6.Exhibits45SIGNATURES46 PARTI—FINANCIAL INFORMATION PHIBRO ANIMAL HEALTH CORPORATION AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF OPERATIONS PHIBRO ANIMAL HEALTH CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) PHIBRO ANIMAL HEALTH CORPORATION AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS PHIBRO ANIMAL HEALTH CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS PHIBRO ANIMAL HEALTH CORPORATION AND SUBSIDIARIES NOTESTO CONSOLIDATED FINANCIAL STATEMENTS(in thousands, except per share amounts)(unaudited) 1.Description of Business Phibro Animal Health Corporation (“Phibro” or “PAHC”) and its subsidiaries (together, the “Company”) is adiversified global developer, manufacturer and marketer of a broad range of animal health and mineral nutritionproducts for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture and dogs. TheCompany is also a manufacturer and marketer of performance products for use in the personal care, industrial chemicaland chemical catalyst industries. Unless otherwise indicated or the context requires otherwise, references in this reportto “we,” “our,” “us,” and similar expressions refer to Phibro and its subsidiaries. The unaudited consolidated financial information for the three and six months ended December31,2025 and2024, is presented on the same basis as the financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended June30,2025 (the “Annual Report”), filed with the Securities and Exchange Commissionon August 27, 2025 (File no. 001-36410). In the opinion of management, these financial statements include alladjustments necessary for a fair statement of the financial position, results of operations and cash flows of theCompany for the interim periods, and the adjustments are of a normal and recurring nature. The financial results forany interim period are not necessarily indicative of the results for the full year. The consolidated balance sheetinformation as of June30,2025 was derived from the audited consolidated financial statements but does not includeall disclosures req